Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Overfeeding Followed by Weight Loss on Liver Fat Content and Adipose Tissue Inflammation

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by Helsinki University
Sponsor:
Information provided by (Responsible Party):
Sanja Sadevirta, Helsinki University
ClinicalTrials.gov Identifier:
NCT02133144
First received: May 5, 2014
Last updated: May 6, 2014
Last verified: May 2014
  Purpose

A. BACKGROUND Accumulation of fat in the liver due to non-alcoholic causes (NAFLD) is associated with hepatic insulin resistance, which impairs the ability of insulin to inhibit the production of glucose and VLDL . This leads to increases in serum glucose, insulin and triglyceride concentrations as well as hyperinsulinemia. Recent epidemiologic studies have shown that a major reason for the metabolic syndrome as well as the accompanying increased risk of cardiovascular disease and type 2 diabetes is overconsumption of simple sugars. The investigators have recently shown that overeating simple sugars (1000 extra calories/day, "CANDY" diet) increases liver fat content by 30% within 3 weeks (4), and recapitulates features of the metabolic syndrome such as hypertriglyceridemia and a low HDL cholesterol concentration.

The fatty acids in intrahepatocellular triglycerides may originate from peripheral lipolysis, de novo lipogenesis, uptake of chylomicron remnants by the liver and from hepatic uptake of fatty acids released during intravascular hydrolysis of triglyceride-rich lipoproteins (the spillover pathway). A classic study using stable isotope methodology by the group of Elisabeth Parks showed that in subjects with NAFLD, the excess intrahepatocellular triglycerides originate from peripheral lipolysis and de novo lipogenesis.

It is well-established that ingestion of a high carbohydrate as compared to high fat diet stimulates de novo lipogenesis in humans. Meta-analyses comparing isocaloric high fat and high carbohydrate diets have shown that high carbohydrate but not high fat diets increase increase serum triglycerides and lower HDL cholesterol. Since hypertriglyceridemia results from overproduction of VLDL from the liver, these data suggest the composition of the diet influences hepatic lipid metabolism. Whether this is because overfeeding fat leads to preferential deposition of fat in adipose tissue while high carbohydrate diets induce a relative greater increase in liver fat is unknown. There are no previous studies comparing effects of chronic overfeeding of fat as compared to carbohydrate on liver fat or and the sources of intrahepatic fatty acids.

A common polymorphism in PNPLA3 at rs738409 (adiponutrin) gene is associated with a markedly increase liver fat content. This finding has been replicated in at least 20 studies across the world. The investigators have shown that PNPLA3 is regulated by the carbohydrate response element binding protein 1. Mice overexpressing the human I148M PNPLA3 variant in the liver exhibit an increase in liver triglycerides and cholesteryl esters on a high sucrose but not high fat diet. These data suggest that overfeeding a high carbohydrate as compared to a high fat diet may increase liver fat more in subjects carrying the I148M allele than in non-carriers.

B. HYPOTHESIS The investigators hypothesize that overfeeding a high fat as compared to an isocaloric high carbohydrate diet influences the source of intrahepatocellular triglycerides. During a high fat diet, relatively more of intrahepatocellular triglycerides originate from peripheral lipolysis and less from DNL than during a high carbohydrate diet in the face of a similar increase in liver fat. It is also possible given the lack of previous overfeeding data comparing 2 different overfeeding diets that the high fat diet induces a smaller increase in liver fat than a high carbohydrate diet even in the face of an identical increase in caloric intake because a greater fraction of ingested fat is channeled to adipose tissue than the liver. The investigators also hypothesize that liver fat may increase more in carriers than non-carriers of the I148M variant in PNPLA3 during a high carbohydrate than a high fat diet.

C. SPECIFIC AIMS The investigators wish to randomize, using the method of minimization (considers baseline age, BMI, gender, liver fat, PNPLA3 genotype) 40 non-diabetic subjects with NAFLD as determined by the non-invasive score developed in our laboratory or previous knowledge of liver fat content based on MRS to overeat either a high carbohydrate or high fat diet (1000 extra calories per day) for 3 weeks. Before and after the overfeeding diets, will measure liver fat content by 1H-MRS and the rate of adipose tissue lipolysis using doubly labeled water (DDW) and [1,1,2,3,3-2H5] glycerol as described in detail below. The investigators also wish to characterize glucose, insulin, fatty acid and triacylglyceride profiles before and while on the experimental diet. An adipose tissue biopsy is taken to determine whether expression of genes involved in lipogenesis or lipolysis, or those involved in adipose tissue inflammation change in response to overfeeding, and for measurement of LPL activity. After overfeeding, both groups will undergo weight loss to restore normal weight as described in our recent study. The metabolic study is repeated after weight loss.


Condition Intervention
NAFLD
Behavioral: overeating fat
Behavioral: overeating carbohydrate

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Effects of Overfeeding Followed by Weight Loss on Liver Fat Content and Adipose Tissue Inflammation

Resource links provided by NLM:


Further study details as provided by Helsinki University:

Primary Outcome Measures:
  • Liver fat content (1H-MRS) and intra-abdominal and subcutaneous fat (MRI) [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
  • De novo lipogenesis (DNL) and measurement of lipolysis [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
    the rate of DNL and adipose tissue lipolysis is measured using doubly labeled water (DDW) and [1,1,2,3,3-2H5] glycerol


Secondary Outcome Measures:
  • Analytical procedures [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
    Laboratory tests including fasting glucose, insulin, C-peptide, liver enzymes, total, LDL and HDL cholesterol and TG concentrations PNPLA3 genotyping is performed also


Other Outcome Measures:
  • Biopsies and analysis of subcutaneus adipose tissue [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]
    Needle biopsies of abdominal subcutaneus tissue will be taken for subsequent isolation of RNA for measurements of gene expression (by quantitative PCR). Fat cell size is also measured.

  • Indirect calorimetry [ Time Frame: 3 week ] [ Designated as safety issue: No ]
    Indirect calorimetry is the method by which metabolic rate is estimated from measurements of oxygen (O2) consumption and carbon dioxide (CO2) production.


Estimated Enrollment: 40
Study Start Date: February 2014
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: High fat diet
Intervention: overeating high fat diet (1000 extra calories per day) for 3 weeks
Behavioral: overeating fat Behavioral: overeating carbohydrate
Experimental: High carbohydrate diet
Intervention: overeating high carbohydrate diet (1000 extra calories per day) for 3 weeks
Behavioral: overeating fat Behavioral: overeating carbohydrate

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • BMI 27-35 kg/m2
  • Age 18-65 yrs

Exclusion Criteria:

  • type 1 or 2 diabetes
  • renal insufficiency
  • pre-existing liver or significant other disease other than NAFLD (i.e. autoimmune, viral or drug-induced liver disease)
  • excessive use of alcohol (over 20g/day)
  • pregnancy or lactation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02133144

Contacts
Contact: Sanja Sadevirta, MD +358 9 471 71886 sanja.sadevirta@hus.fi

Locations
Finland
Clinical studies: Biomedicum 2U, Tukholmankatu 8, 00290 Helsinki, Rooms 106b and 105b Recruiting
Helsinki, Finland, 00290
Contact: Anne Salo, Study nurse       anne.salo@hus.fi   
Principal Investigator: Sanja Sadevirta, MD         
Sponsors and Collaborators
Helsinki University
Investigators
Principal Investigator: Hannele Yki-Jarvinen, FRCP Department of Medicine, Divisions of Diabetes2, Helsinki University Central Hospital, Helsinki, Finland
  More Information

No publications provided

Responsible Party: Sanja Sadevirta, MD, Helsinki University
ClinicalTrials.gov Identifier: NCT02133144     History of Changes
Other Study ID Numbers: 322013
Study First Received: May 5, 2014
Last Updated: May 6, 2014
Health Authority: Finland: Ethics committee of the Helsinki University Central Hospital

Keywords provided by Helsinki University:
NAFLD
insulin resistance
metabolic syndrome
de novo lipogenesis
overfeeding

Additional relevant MeSH terms:
Inflammation
Weight Loss
Body Weight
Body Weight Changes
Pathologic Processes
Signs and Symptoms

ClinicalTrials.gov processed this record on November 20, 2014